A Study to Evaluate the Safety and Pharmacokinetics of AD-228A Compared to Coadministration of AD-2281 and AD-2282
NCT ID: NCT06858865
Last Updated: 2025-10-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
60 participants
INTERVENTIONAL
2025-07-12
2025-08-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Safety and Pharmacokinetics of AD-221 Compared to Coadministration of AD-221A and AD-221B
NCT05202405
A Study to Compare to PK Characteristics and Safety Profiles Between AD-117 and AD-117A
NCT07152873
A Study to Evaluate the Efficacy and Safety of Co-administration of AD-2281 and AD-2282
NCT06747936
A Study to Evaluate the Efficacy and Safety of AD-221 and AD-221A
NCT05131997
Evaluating the Pharmacokinetic Interaction Between AD-2011 and AD-2012
NCT03586037
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sequence A
Period 1 : Reference Drug(AD-2281 and AD-2282), Period 2 : Test Drug(AD-228A)
AD-228A
AD-228A Oral Tablet
AD-2281 and AD-2282
AD-2281 Oral Tablet + AD-2282 Oral Tablet
Sequence B
Period 1 : Test Drug(AD-228A), Period 2 : Reference Drug(AD-2281 and AD-2282)
AD-228A
AD-228A Oral Tablet
AD-2281 and AD-2282
AD-2281 Oral Tablet + AD-2282 Oral Tablet
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AD-228A
AD-228A Oral Tablet
AD-2281 and AD-2282
AD-2281 Oral Tablet + AD-2282 Oral Tablet
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The Age equal to or greater than 19 in healthy volunteers at the time of screening visit
Exclusion Criteria
* Other exclusions applied
19 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Addpharma Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
H+ Yangji Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AD-228BE-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.